Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
First patient treated in FDA IDE study of Aqua Medical’s PIMA device
Aqua Medical has treated the first West Coast patient in the RESTORE-I trial, a Food and Drug Administration (FDA)-approved investigational …
-
Enrolment concludes in Lynch’s Phase II rhPDGF-BB study
Lynch Regenerative Medicine has completed participant enrolment in a Phase II clinical trial assessing the recombinant human pure platelet-derived growth …
-
BeOne Medicines and partners renew Brukinsa access programme for CLL
BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for …
-
J&J secures FDA clearance for MONARCH QUEST 3 bronchoscopy system
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) 510(k) clearance for the MONARCH QUEST 3 …
-
Leal Therapeutics raises $30m to fund schizophrenia and ALS trials
Leal Therapeutics has completed a $30m extension of its Series A financing to support advancement of its investigational therapies for …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Fulcrum and Slate Medicines sign merger agreement
Fulcrum Therapeutics and Slate Medicines have signed a definitive agreement to merge in an all-stock transaction backed by a $245m …
-
Nanochon secures Panamá’s approval for trial of knee cartilage implant
Nanochon has secured the Panamá’s Ministry of Health approval to begin its first-in-human trial of Chondrograft, an implant intended to …
-
FDA approves ArkBio’s ziresovir for Phase II trial in severe RSV
Shanghai Ark Biopharmaceutical (ArkBio) has received approval from the US Food and Drug Administration (FDA) to begin a Phase II …
-
FDA grants fast track status to Phanes’ spevatamig for advanced BTC
Phanes Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for spevatamig to treat patients …
-
Optellum and Coreline Soft plan AI integration for lung nodule care
Optellum and Coreline Soft have announced plans to integrate AI to support lung nodule detection and management across international markets …
-
SCRI and MSD to broaden US oncology trial access
Sarah Cannon Research Institute (SCRI) and Merck & Co (MSD) have entered a collaboration aimed at increasing patient access to …
-
Xanadu and University of Alberta to develop quantum algorithms for cancer
Xanadu Quantum Technologies and the University of Alberta in Canada have formed a research partnership focused on advancing algorithms to …
-
Freenome’s lung cancer test receives FDA breakthrough status
Freenome has secured breakthrough device designation from the US Food and Drug Administration (FDA) for its investigational, blood-based SimpleScreen Lung …
-
Remepy secures $36m funding for hybrid drug pipeline expansion
Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug …
-
Enrolment concludes in BD’s PREVENT trial of Phasix Mesh
Becton, Dickinson and Company (BD) has completed patient enrolment in the PREVENT clinical trial, which is evaluating the use of …
